- New Obama adviser Podesta is against Keystone but will steer clear of pipeline deliberations
- 40 Australian adults, children found in ‘one of the worst accounts of incest ever made public’
- Venezuela’s Maduro calls on student ‘price vigilantes’ to hit the streets, report businesses
- Atheists smug as Hindus join Satanists to demand display at Oklahoma Statehouse
- Bow before Valkyrie, NASA’s ‘superhero robot’ entry in DARPA challenge
- 10-year-old Pennsylvania boy suspended for pretend bow-and-arrow shooting
- Tea partiers turn on Capitol Hill budget deal
- Budget deal to get quick vote in the House
- Comma on!: Twitter erupts over Obama-Castro ‘marriage’
- Sebelius calls for review of Obamacare rollout woes
Antibiotic-resistant ‘superbugs’ alarm health care industry
Health officials are warning of the rise of the “superbugs” — bacteria and other pathogens that cannot be killed by modern medicine.
But many pharmaceutical companies are resisting the call to develop effective antibiotics and instead are shifting their resources to other products.
Exhibit A is AstraZeneca, one of the major companies still working on developing antibiotics.
Its new chief executive, Pascal Soriot, said Monday the drug giant was restructuring its workforce and will focus on three therapy areas: cancer, cardiovascular and metabolism disorders, and respiratory and inflammatory diseases. This means “reduced spending on anti-infectives,” according to Reuters.
Pfizer, Roche, Bristol-Myers Squibb and Eli Lilly have all reduced or eliminated their antibiotic research efforts, while Merck & Co. and GlaxoSmithKline are still actively pursuing such medicines, Reuters added.
The reason businesses resist making new antibiotics is rational: The drugs are expensive to develop but are used briefly by most patients and are aimed at pathogens that eventually learn how to build up a resistance to them.
As a result, there have always been relatively few antibiotic products in development, and now — gauging by what is in the pipeline — “none of them really is going to be active against these bacteria in the near term,” said Dr. Gary A. Roselle, national director of the Infectious Diseases Service for the Department of Veterans Affairs health care system.
“Incentivization” for drug development that may not have major monetary success is a big topic of discussion, added Dr. Roselle, who works at the Veterans Affairs Medical Center in Cincinnati. But in the meantime, “The current goal has to be prevention, wherever possible,” he said.
Public warnings have been issued about multidrug-resistant tuberculosis and gonorrhea, and a hospital-associated infection known as methicillin-resistant Staphylococcus aureus.
A new bug, described as a “nightmare bacteria,” was highlighted in early March by Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention.
Carbapenem-resistant Enterobacteriaceae (CRE) refers to a family of mostly harmless bacteria that live in the gut, and includes E. coli, shigella, salmonella and klebsiella. These bacteria can cause illnesses, including pneumonia, diarrhea and urinary tract infections, if they are swallowed or enter the bloodstream through an open wound.
Carbapenem-resistant refers to some bacteria that become immune to even the “last-resort” class of drugs.
CRE “pose a triple threat” because few, if any, antibiotics can kill them; they are associated with a high mortality rate; and “they can spread their resistance to other bacteria,” Dr. Frieden said.
That last point is of great concern, Dr. Frieden said, because if CRE pathogens transfer their drug-resistance genes to another bacteria such as E. coli, it could make a common illness, such as a urinary tract infection, extremely difficult to treat.
Reports of the rise of the rare but potentially deadly CRE superbugs caught the attention of lawmakers on Capitol Hill.
© Copyright 2013 The Washington Times, LLC. Click here for reprint permission.
About the Author
Cheryl Wetzstein covers family and social issues as a national reporter for The Washington Times. She has been a reporter for three decades, working in New York City and Washington, D.C. Since joining The Washington Times in 1985, she has been a features writer, environmental and consumer affairs reporter, and assistant business editor.
Beginning in 1994, Mrs. Wetzstein worked exclusively ...
- Study IDs reasons for late-term abortions
- Panel seeks 'surveillance' system for gay blood donors
- Pregnancies decline overall, up among older women
- Embryonic stem cell research falls out of favor as scientists go ethical
- With new HIV research, FDA may let gay men donate blood
Latest Blog Entries
- Pro-life, stem-cell bill signed into law by Kansas Gov. Sam Brownback
- N. Dakota lawmakers approve tough abortion bill
- Pope Benedict XVI's successor should allow priests to get a new title: Husband, poll finds
- House votes to reject Obama welfare shift
- Report: Two out of three Democrats support gay marriage
By Donald Lambro
Growth spikes are little more than trend-free anomalies
- Tea partiers turn on Capitol Hill budget deal
- Rand Paul: Budget deal 'shameful,' 'huge mistake'
- Leon Panetta named as source of 'Zero Dark Thirty' scriptwriters information
- Teen thugs in DC run wild -- even while wearing GPS ankle bracelets
- New budget accord saves $23 billion -- after $65 billion spending spree
- CARSON: Why did the founders give us the Second Amendment?
- American bourbon now better than Scottish whiskey: U.K.-born expert
- Obama takes 'selfie' at Mandela's funeral service
- VEGAS RULES: Harry Reid pushed feds to change ruling for casino's big-money foreigners
- U.S. pilot scares off Iranians with 'Top Gun'-worthy stunt: 'You really ought to go home'
Independent voices from the The Washington Times Communities
An objective, analysis-based perspective of D.C. sports as seen through the eyes of lifelong D.C. sports enthusiast, John Heibel.
All of the world’s problems, solved on your back porch
Human interest stories to feed interest, satisfy curiosity and see outside the box.
Politics, economics, and business from a real world perspective.
White House pets gone wild!
Let it snow